Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
WOBURN, Mass., March 22, 2011 /PRNewswire/ -- Avantra Biosciences has announced they are selling their new and improved proprietary PATH® Protein Microarray Ultra-thin Nitrocellulose Slides. Additionally, Avantra is discussing the possibility of partnering with certain parties to expand the distribution network for the PATH slides.
The PATH Slide is the first protein microarray slide to provide the many benefits of nitrocellulose in a thin film that allows very low background fluorescence and excellent signal-to-noise ratio.
"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Brendan McKernan, President of Avantra Biosciences. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH surface chemistry to be far superior to other commercially available protein-array surfaces."
Key Features:
- Excellent stability and shelf life
- Best in class sensitivity, accuracy, and reproducibility and dynamic range providing excellent spot morphology, retained protein conformation and functional activity.
- Low background and increased dynamic range – proprietary ultra-thin nitrocellulose provides enhances signal-to-noise ratios
- Standard slide format – adaptable to all commonly used slide format microarray readers
Ordering information
Email: [email protected]
Phone: 877.395.7608
Fax: 617.892.7191
About Avantra Biosciences Corporation
Avantra Biosciences is a privately held diagnostics company that has pioneered next generation technology for protein biomarker analysis. The PATH technology is integrated into the Avantra Q400 Biomarker Workstation. Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.
Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.
SOURCE Avantra Biosciences
Share this article